Table 2.
Comparison between P-anti-M3R positive and negative SS patients.
| Plasma anti-M3R (−), n=24 | Plasma anti-M3R (+), n=117 | P value | |
|---|---|---|---|
| Ocular symptoms* | 20 (83.3%) | 93 (79.5%) | 0.785 |
| Ocular signs* | 17 (70.8%) | 95 (81.9%) | 0.217 |
| Schirmer test ≤ 5 mm | 13/23 (56.5%) | 68/103 (66.0%) | 0.390 |
| OSS ≥ 5 | 5/18 (27.8%) | 24/71 (33.8%) | 0.626 |
| Oral symptoms* | 21 (87.5%) | 101 (86.3%) | 1.000 |
| Salivary gland involvement* | 23 (95.8%) | 111/116 (95.7%) | 1.000 |
| Unstimulated WSFR ≤ 0.1 mL/min | 17/23 (73.9%) | 89/110 (80.9%) | 0.448 |
| Abnormal salivary scintigraphy | 16/18 (88.9%) | 95/107 (88.8%) | 1.000 |
| Anti-Ro/SSA (+) | 14 (58.3%) | 114 (97.4%) | 6.672×10 −7 |
| Anti-La/SSB (+) | 4 (16.7%) | 65 (55.6%) | 0.001 |
| Focus score ≥1 | 13/19 (68.4%) | 59/69 (85.5%) | 0.087 |
| Focus score ≥2 | 4/19 (21.1%) | 33/69 (47.8%) | 0.042 |
| Chisholm–Mason grade = 4 | 5/19 (26.3%) | 41/69 (59.4%) | 0.011 |
| ESSDAI ≥5 | 2 (8.3%) | 20 (17.1%) | 0.368 |
| Extraglandular manifestations | 12 (50.0%) | 65 (55.6%) | 0.619 |
| Raynaud’s phenomenon | 2 (8.3%) | 31 (26.5%) | 0.065 |
| Leukopenia | 3 (12.5%) | 38 (32.5%) | 0.052 |
| Hypocomplementemia C3 or C4 | 1/23 (4.3%) | 12/115 (10.4%) | 0.695 |
| Total IgG ≥ 1700 mg/dL | 10/23 (43.5%) | 79 (67.5%) | 0.028 |
P values were calculated by chi-square or Fischer’s exact test as applicable.
*,
defined according to the 2002 AECG classification criteria.